-
公开(公告)号：US20180223173A1
公开(公告)日：2018-08-09
申请号：US15750026
申请日：2016-07-28
申请人： STEPAN COMPANY
IPC分类号： C09K8/592 , C07C309/24 , C07C309/19 , C07C309/04 , C07C309/05 , C07C309/10 , C07C303/22 , C07C303/20 , C09K8/584 , E21B43/24
CPC分类号： C09K8/592 , C07C303/20 , C07C303/22 , C07C309/04 , C07C309/05 , C07C309/10 , C07C309/19 , C07C309/24 , C07C2601/14 , C09K8/584 , C11D1/143 , C11D1/22 , E21B37/06 , E21B41/02 , E21B43/2408
摘要： Mixed dimer and mixed oligomer compositions are disclosed. The mixed dimer compositions comprise a monosulfonated cross-dimer or a salt thereof. The monosulfonated cross-dimer is a reaction product of (a) an alpha-olefin sulfonic acid (AOS acid); and (b) an unsulfonated olefin, an unsulfonated olefin precursor, or a functionalized olefin. The mixed oligomer compositions comprise a mono- or polysulfonated cross-oligomer or a salt thereof. The mono- or polysulfonated cross-oligomer is a reaction product of (a) an AOS acid; and (b) an unsulfonated diolefin or an unsulfonated diolefin precursor. Various methods for making the mixed dimer or oligomer compositions are described. Salts of the mixed dimer and oligomer compositions are useful surfactants for foams used in oilfield and other applications. The foams have improved high-temperature stability when compared with foams from AOS dimer acid salts.
-
公开(公告)号：US20180170862A1
公开(公告)日：2018-06-21
申请号：US15577417
申请日：2016-06-01
发明人： Zhong-Yin Zhang , Rongjun He
IPC分类号： C07C309/24 , A61P35/00 , A61P35/02 , C07D235/10 , C07D277/82 , C07D211/16 , C07D211/18 , C07D215/08 , C07D233/61 , C07D285/135 , C07D277/46 , C07D333/20 , C07D231/40 , C07D307/68 , C07D295/135 , C07D215/38 , C07C309/18
CPC分类号： C07C309/24 , A61K45/06 , A61P3/10 , A61P25/28 , A61P31/06 , A61P35/00 , A61P35/02 , C07C309/17 , C07C309/18 , C07D211/16 , C07D211/18 , C07D215/08 , C07D215/38 , C07D231/40 , C07D233/61 , C07D233/64 , C07D235/10 , C07D235/14 , C07D277/46 , C07D277/82 , C07D285/135 , C07D295/135 , C07D307/68 , C07D333/20
摘要： Small molecule compounds derived from α-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.
-
公开(公告)号：US20180079762A1
公开(公告)日：2018-03-22
申请号：US15715245
申请日：2017-09-26
申请人： AbbVie Inc.
发明人： Benoit Cardinal-David , Vincent S. Chan , Kassibla Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Eric A. Voight , Zhi Wang , Geoff G. Zhang , Valentino J. Stella
IPC分类号： C07F9/09 , A61K31/661 , C07F9/06 , A61K45/06 , C07C47/277 , C07C309/24 , C07C281/02 , A61K31/6615
CPC分类号： C07F9/094 , A61K31/661 , A61K31/6615 , A61K45/06 , C07B2200/13 , C07C47/277 , C07C281/02 , C07C309/24 , C07F9/06 , A61K2300/00
摘要： The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20180039175A1
公开(公告)日：2018-02-08
申请号：US15666757
申请日：2017-08-02
CPC分类号： G03F7/0045 , C07C69/753 , C07C303/32 , C07C309/04 , C07C309/06 , C07C309/17 , C07C309/19 , C07C309/23 , C07C309/24 , C07C309/29 , C07C309/30 , C07C309/31 , C07C309/32 , C07C309/35 , C07C309/44 , C07C309/58 , C08F212/02 , C08F220/22 , C08F220/24 , C08F220/30 , C08F220/38 , C08F222/10 , C08F224/00 , C08F228/02 , C08F2220/283 , C08F2220/303 , C08F2220/382 , G03F7/0046 , G03F7/0382 , G03F7/162 , G03F7/168 , G03F7/2006 , G03F7/2037 , G03F7/322 , G03F7/38
摘要： A negative resist composition comprising (A) a sulfonium compound of betaine type and (B) a polymer is provided. The resist composition is effective for controlling acid diffusion during the exposure step, exhibits a very high resolution during pattern formation, and forms a pattern with minimal LER.
-
5.发明申请公开(公告)号：US20170158731A1
公开(公告)日：2017-06-08
申请号：US15434095
申请日：2017-02-16
IPC分类号： C07K1/13 , C07C309/24 , C07K7/08 , C07B59/00 , C07D207/46 , C07D327/04 , C07C303/22
CPC分类号： C07K1/13 , C07B59/00 , C07B59/001 , C07B59/002 , C07B2200/05 , C07C303/22 , C07C309/22 , C07C309/24 , C07D207/404 , C07D207/46 , C07D209/60 , C07D327/04 , C07K7/08
摘要： Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio)molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conform to respective formulae (Ip) and (I): Also disclosed are methods for producing these precursors and compounds, as well as for conjugation of these compounds with (bio)molecules, and to the drugs obtained by this method.
-
公开(公告)号：US09611215B2
公开(公告)日：2017-04-04
申请号：US14647144
申请日：2013-11-22
IPC分类号： C07D207/46 , C07D327/04 , C07C309/24 , C07B59/00 , C07D207/404 , C07D209/60 , C07C309/22 , C07K1/13 , C07K7/08
CPC分类号： C07K1/13 , C07B59/00 , C07B59/001 , C07B59/002 , C07B2200/05 , C07C303/22 , C07C309/22 , C07C309/24 , C07D207/404 , C07D207/46 , C07D209/60 , C07D327/04 , C07K7/08
摘要： Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio)molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conform to respective formulae (Ip) and (I): Also disclosed are methods for producing these precursors and compounds, as well as for conjugation of these compounds with (bio)molecules, and to the drugs obtained by this method.
-
7.发明申请CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES 审中-公开环烷基羟基化合物及其组合物用于胆固醇管理及相关用途公开(公告)号：US20170073286A1
公开(公告)日：2017-03-16
申请号：US15274436
申请日：2016-09-23
IPC分类号： C07C31/27 , C07C69/757 , C07C47/34 , C07C309/25 , C07F9/11 , C07C59/11 , C07C59/29 , C07D495/04 , C07C255/00 , C07F9/24 , C07D257/04 , C07D261/12 , C07D309/12 , C07D305/12 , C07D307/33 , C07D309/30 , C07C61/12
CPC分类号： C07C31/27 , A61K31/191 , A61K31/194 , A61K31/20 , A61K31/23 , C07C31/20 , C07C31/22 , C07C31/24 , C07C33/26 , C07C47/19 , C07C47/34 , C07C59/01 , C07C59/105 , C07C59/11 , C07C59/245 , C07C59/285 , C07C59/29 , C07C59/46 , C07C59/48 , C07C59/54 , C07C61/12 , C07C62/02 , C07C62/06 , C07C65/17 , C07C69/003 , C07C69/017 , C07C69/675 , C07C69/757 , C07C255/00 , C07C309/08 , C07C309/24 , C07C309/25 , C07C2101/02 , C07C2101/04 , C07C2101/08 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D213/80 , C07D257/04 , C07D261/08 , C07D261/12 , C07D305/12 , C07D307/33 , C07D309/10 , C07D309/12 , C07D309/30 , C07D405/12 , C07D495/04 , C07F9/093 , C07F9/094 , C07F9/11 , C07F9/117 , C07F9/12 , C07F9/2408 , C07F9/2416 , C07F9/242 , C07F9/2425 , C07F9/4423
摘要： The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
摘要翻译： 本发明涉及新的环烷基 - 羟基化合物，包含羟基化合物的组合物和可用于治疗和预防各种疾病和病症例如但不限于老化，阿尔茨海默氏病，癌症，心血管疾病，糖尿病性肾病，糖尿病 视网膜病变，葡萄糖代谢紊乱，血脂异常，脂蛋白血症，高血压，阳ence，炎症，胰岛素抵抗，胆汁中的脂质消除，肥胖，胆汁中的氧固醇消除，胰腺炎，帕金森病，过氧化物酶体增殖物激活受体相关病症，磷脂消除 胆汁，肾脏疾病，败血症，X综合征，血栓形成障碍。 本发明的化合物和方法也可用于调节C反应蛋白或增强患者的胆汁产生。 在某些实施方案中，本发明的化合物，组合物和方法可用于与其它治疗剂如降胆固醇和降血糖药物组合治疗。
-
8.发明申请Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer 审中-公开使用2,5-二羟基苯化合物和衍生物治疗皮肤癌公开(公告)号：US20170065547A1
公开(公告)日：2017-03-09
申请号：US15336208
申请日：2016-10-27
发明人： Pedro Cuevas Sànchez , Guillermo Gimenez Gallego , Inigo Saenz de Tejada Gorman , Javier Angulo Frutos , Serafin Valverde Lopez , Antonio Romero Garrido , Rosa Maria Lozano Puerto
IPC分类号： A61K31/255 , A61K31/095 , A61K45/06 , A61K31/192 , A61K9/00
CPC分类号： A61K31/255 , A61K9/0014 , A61K31/095 , A61K31/10 , A61K31/185 , A61K31/192 , A61K31/216 , A61K31/222 , A61K31/225 , A61K31/235 , A61K45/06 , C07C57/44 , C07C59/68 , C07C65/03 , C07C65/19 , C07C69/017 , C07C69/84 , C07C309/24 , C07C309/42 , C07C309/68 , C07C309/75 , A61K2300/00
摘要： The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.
摘要翻译： 本发明涉及式（I）的2,5-二羟基苯衍生物或其药学上可接受的盐，溶剂化物，异构体或前药在治疗和/或预防皮肤癌中的用途。
-
9.发明授权公开(公告)号：US09452964B2
公开(公告)日：2016-09-27
申请号：US14674025
申请日：2015-03-31
IPC分类号： C07C31/27 , C07C61/12 , C07C47/34 , C07C309/25 , C07F9/24 , C07D261/12 , C07C59/105 , C07C33/26 , C07C47/19 , C07C69/675 , C07C69/003 , C07C69/017 , C07C309/08 , C07F9/11 , C07C309/24 , C07F9/12 , C07D495/04 , C07C255/00 , C07D257/04 , C07D261/08 , C07D305/12 , C07D307/33 , C07C59/01 , C07D309/30 , C07C31/20 , C07C31/22 , C07C31/24 , C07C59/11 , C07C59/245 , C07C59/285 , C07C59/29 , C07C59/46 , C07C59/48 , C07C59/54 , C07C62/02 , C07C62/06 , C07C65/17 , C07C69/757 , C07D213/80 , C07D309/10 , C07D309/12 , C07D405/12 , C07F9/09 , C07F9/117 , C07F9/44
CPC分类号： C07C31/27 , A61K31/191 , A61K31/194 , A61K31/20 , A61K31/23 , C07C31/20 , C07C31/22 , C07C31/24 , C07C33/26 , C07C47/19 , C07C47/34 , C07C59/01 , C07C59/105 , C07C59/11 , C07C59/245 , C07C59/285 , C07C59/29 , C07C59/46 , C07C59/48 , C07C59/54 , C07C61/12 , C07C62/02 , C07C62/06 , C07C65/17 , C07C69/003 , C07C69/017 , C07C69/675 , C07C69/757 , C07C255/00 , C07C309/08 , C07C309/24 , C07C309/25 , C07C2101/02 , C07C2101/04 , C07C2101/08 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07D213/80 , C07D257/04 , C07D261/08 , C07D261/12 , C07D305/12 , C07D307/33 , C07D309/10 , C07D309/12 , C07D309/30 , C07D405/12 , C07D495/04 , C07F9/093 , C07F9/094 , C07F9/11 , C07F9/117 , C07F9/12 , C07F9/2408 , C07F9/2416 , C07F9/242 , C07F9/2425 , C07F9/4423
摘要： The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
-
公开(公告)号：US09446059B2
公开(公告)日：2016-09-20
申请号：US14919418
申请日：2015-10-21
申请人： AbbVie Inc.
发明人： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Eric A. Voight , Zhi Wang , Geoff G. Zhang , Valentino J. Stella
IPC分类号： A61K31/661 , C07F9/06 , A61K31/6615
CPC分类号： C07F9/094 , A61K31/661 , A61K31/6615 , A61K45/06 , C07B2200/13 , C07C47/277 , C07C281/02 , C07C309/24 , C07F9/06 , A61K2300/00
摘要： The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
摘要翻译： 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。
-
-
-
-
-
-
-
-
-
搜索结果
252 条记录 (耗时 0.029 秒)
